NovoCure Limited: research and development expense
Research and development expense for NovoCure Limited. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All NovoCure Limited financial histories
What this measure means
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
Exact concept: us-gaap:ResearchAndDevelopmentExpense. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2013-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 224,544,000 | USD | 2026-02-26 | 10-K · 0001645113-26-000017 |
| 2024-01-01 | 2024-12-31 | 209,645,000 | USD | 2026-02-26 | 10-K · 0001645113-26-000017 |
| 2023-01-01 | 2023-12-31 | 223,062,000 | USD | 2026-02-26 | 10-K · 0001645113-26-000017 |
| 2022-01-01 | 2022-12-31 | 206,085,000 | USD | 2025-02-27 | 10-K · 0001645113-25-000002 |
| 2021-01-01 | 2021-12-31 | 201,303,000 | USD | 2024-02-22 | 10-K · 0001645113-24-000006 |
| 2020-01-01 | 2020-12-31 | 132,010,000 | USD | 2023-02-23 | 10-K · 0001645113-23-000023 |
| 2019-01-01 | 2019-12-31 | 79,003,000 | USD | 2022-02-24 | 10-K · 0001645113-22-000011 |
| 2018-01-01 | 2018-12-31 | 50,574,000 | USD | 2021-02-25 | 10-K · 0001645113-21-000017 |
| 2017-01-01 | 2017-12-31 | 38,103,000 | USD | 2020-02-27 | 10-K · 0001645113-20-000025 |
| 2016-01-01 | 2016-12-31 | 41,467,000 | USD | 2019-02-28 | 10-K · 0001564590-19-005146 |
| 2015-01-01 | 2015-12-31 | 43,748,000 | USD | 2018-02-22 | 10-K · 0001564590-18-002766 |
| 2014-01-01 | 2014-12-31 | 40,381,000 | USD | 2017-02-23 | 10-K · 0001564590-17-002097 |
| 2013-01-01 | 2013-12-31 | 34,797,000 | USD | 2016-03-01 | 10-K · 0001564590-16-013777 |
Related financial histories
- NovoCure Limited: total assets
- NovoCure Limited: total liabilities
- NovoCure Limited: stockholders equity
- NovoCure Limited: cash and cash equivalents
- NovoCure Limited: net income or loss
- NovoCure Limited: operating cash flow
- NovoCure Limited: capital expenditure payments
- NovoCure Limited: revenue
- NovoCure Limited: financing cash flow
- NovoCure Limited: investing cash flow
- NovoCure Limited: retained earnings or deficit
- NovoCure Limited: basic weighted-average shares
- NovoCure Limited: diluted weighted-average shares
- NovoCure Limited: basic earnings per share
- NovoCure Limited: diluted earnings per share
- NovoCure Limited: income tax expense or benefit
- NovoCure Limited: net property, plant and equipment
- NovoCure Limited: share-based compensation expense
- NovoCure Limited: operating income or loss
- NovoCure Limited: current assets
- NovoCure Limited: interest expense
- NovoCure Limited: current liabilities
- NovoCure Limited: net current accounts receivable
- NovoCure Limited: operating expenses
- NovoCure Limited: net inventory
- NovoCure Limited: gross profit
- NovoCure Limited: cost of revenue
Inspect the source
- Entity
- NovoCure Limited / CIK 0001645113
- Captured
- 2026-09-21T17:23:10.879Z
- SEC response SHA-256
341f267dfdfd4e13271c12e8417a069d35bde3287b9036eee37c7d8e5e7e91f9
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001645113.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))